Results 221 to 230 of about 1,082,657 (258)

Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Clinical Pharmacology &Therapeutics, EarlyView.
Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100–250 mg).
Abigail K. Mayo, James J. Beaudoin, Jeffrey L. Woodhead, Paul B. Watkins, Kim L. R. Brouwer   +4 more
wiley   +1 more source

Microbiota Regulation of Duodenal Adenoma Development: Bile Acids Join the Team. [PDF]

Cell Mol Gastroenterol Hepatol
Yang W, Cong Y.
europepmc   +1 more source

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, Fabien Reyal, Anne‐Sophie Hamy, Paul Gougis   +12 more
wiley   +1 more source

The Conjugated Bile Acids Profile Suggests a Novel Liver-Muscle Axis Associated With Sarcopenia in Chronic Liver Disease. [PDF]

Liver Int
Iwasa M, Eguchi A, Kohjima M, Miyazaki T, Kitamura H, Takami Y, Yamashita N, Tempaku M, Izuoka K, Kobayashi Y, Takei Y, Honda A, Nakagawa H, Ikegami T, Nakamuta M, Okabe J, Montano-Loza AJ.   +16 more
europepmc   +1 more source

Integrated assessment of rifampicin‐mediated induction of transporters and drug‐metabolizing enzymes in a long‐term human liver tissue chip system

Clinical Pharmacology &Therapeutics, EarlyView.
Rifampicin is a prototypical clinical inducer used in drug–drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin‐mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug‐metabolizing enzymes ...
Mattie E. Hartauer, Raeanne M. Lanphier, Shivam Ohri, Jessica Snyder, Jacqueline B. Tiley, John K. Fallon, Henry Ho, Murat Cirit, Shiny Amala Priya Rajan, Kim L. R. Brouwer   +9 more
wiley   +1 more source

Nanosecond Infrared Laser Sampling of Mouse and Human Liver Tissues for LC-MS/MS Analysis of Bile Acids. [PDF]

Int J Mol Sci
Fuh MM, Hahn J, Heine M, Evangelakos I, Scheja L, Mann O, Worthmann A, Schlüter H, Heeren J.   +8 more
europepmc   +1 more source

Clinical Significance of Acute Kidney Injury in Idiosyncratic Drug‐Induced Liver Injury: A Multicentric Propensity Scores Matched Study

Clinical Pharmacology &Therapeutics, EarlyView.
Clinical significance of acute kidney injury in idiosyncratic drug‐induced liver injury: a multicentric propensity scores matched study. Evidence about the role of acute kidney injury (AKI) in idiosyncratic drug‐induced liver injury (DILI) is still scarce.
José María Pinazo‐Bandera, Hao Niu, Juan Pedro Toro‐Ortiz, Inmaculada Medina‐Caliz, Judith Sanabria‐Cabrera, Aída Ortega‐Alonso, Mercedes Robles‐Díaz, Daniel Enrique Di Zeo‐Sanchez, Nelia Hernández, Fernando Bessone, Vinicius Nunes, Raymundo Paraná, M. Isabel Lucena, Raul J. Andrade, Ismael Alvarez‐Alvarez, Miren García‐Cortés   +15 more
wiley   +1 more source

<i>Parabacteroides distasonis</i> alleviates <i>Clostridioides difficile</i> infection in mice while modulating secondary bile acids. [PDF]

Virulence
Zhao M, Wen B, Ouyang Z, Yang J, Yang H, Zhao J, Qiang C, Wang W, Qin P, Niu Y, Zhao J.   +10 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling to Assess Transporter‐Mediated Drug–Drug Interactions in Support of Labeling Recommendations for Zavegepant Nasal Spray

Clinical Pharmacology &Therapeutics, EarlyView.
Zavegepant nasal spray, a calcitonin gene‐related peptide receptor antagonist indicated for acute treatment of migraine with or without aura in adults, is a substrate for organic anion transporting polypeptide 1B3 (OATP1B3), Na+/taurocholate cotransporting polypeptide (NTCP), P‐glycoprotein (P‐gp), and cytochrome P450 3A4 (CYP3A4).
Alice Ke, Ernesto Callegari, Manthena V.S. Varma, Mayur K Ladumor, Chieko Muto, Richard J. Bertz, Hannah M. Jones, Vaishali Sahasrabudhe, Jing Liu   +8 more
wiley   +1 more source